These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30790616)

  • 1. Modeling neuronopathic storage diseases with patient-derived culture systems.
    Zunke F; Mazzulli JR
    Neurobiol Dis; 2019 Jul; 127():147-162. PubMed ID: 30790616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced pluripotent stem cell models of lysosomal storage disorders.
    Borger DK; McMahon B; Roshan Lal T; Serra-Vinardell J; Aflaki E; Sidransky E
    Dis Model Mech; 2017 Jun; 10(6):691-704. PubMed ID: 28592657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders.
    Plotegher N; Duchen MR
    Trends Mol Med; 2017 Feb; 23(2):116-134. PubMed ID: 28111024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration.
    Audano M; Schneider A; Mitro N
    J Neurochem; 2018 Nov; 147(3):291-309. PubMed ID: 29804302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal storage diseases as disorders of autophagy.
    Settembre C; Fraldi A; Rubinsztein DC; Ballabio A
    Autophagy; 2008 Jan; 4(1):113-4. PubMed ID: 18000397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases.
    Sambri I; D'Alessio R; Ezhova Y; Giuliano T; Sorrentino NC; Cacace V; De Risi M; Cataldi M; Annunziato L; De Leonibus E; Fraldi A
    EMBO Mol Med; 2017 Jan; 9(1):112-132. PubMed ID: 27881461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells.
    Sabitha KR; Chandran D; Shetty AK; Upadhya D
    Stem Cells Dev; 2022 May; 31(9-10):221-238. PubMed ID: 35316126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.
    Platt FM; Boland B; van der Spoel AC
    J Cell Biol; 2012 Nov; 199(5):723-34. PubMed ID: 23185029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodegenerative lysosomal disorders: a continuum from development to late age.
    Nixon RA; Yang DS; Lee JH
    Autophagy; 2008 Jul; 4(5):590-9. PubMed ID: 18497567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal Acid Phosphatase Biosynthesis and Dysfunction: A Mini Review Focused on Lysosomal Enzyme Dysfunction in Brain.
    Ashtari N; Jiao X; Rahimi-Balaei M; Amiri S; Mehr SE; Yeganeh B; Marzban H
    Curr Mol Med; 2016; 16(5):439-46. PubMed ID: 27132795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Lysosomal Storage Disorders to Parkinson's Disease - Challenges and Opportunities.
    Mächtel R; Boros FA; Dobert JP; Arnold P; Zunke F
    J Mol Biol; 2023 Jun; 435(12):167932. PubMed ID: 36572237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPMLs and TPCs: Targets for lysosomal storage and neurodegenerative disease therapy?
    Krogsaeter E; Rosato AS; Grimm C
    Cell Calcium; 2022 May; 103():102553. PubMed ID: 35144097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction.
    Chen C; Sidransky E; Chen Y
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
    Rajan DS; Escolar ML
    Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular Nanorheology Reveals Lysosomal Viscosity as a Reporter for Lysosomal Storage Diseases.
    Devany J; Chakraborty K; Krishnan Y
    Nano Lett; 2018 Feb; 18(2):1351-1359. PubMed ID: 29313356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells.
    Brown RA; Voit A; Srikanth MP; Thayer JA; Kingsbury TJ; Jacobson MA; Lipinski MM; Feldman RA; Awad O
    Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31519738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases.
    Marques ARA; Saftig P
    J Cell Sci; 2019 Jan; 132(2):. PubMed ID: 30651381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions.
    Yañez MJ; Marín T; Balboa E; Klein AD; Alvarez AR; Zanlungo S
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165875. PubMed ID: 32522631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.